é é INSERM : U844, IFR3, Universit Montpellier I é , FR Abstract This review will focus on the interaction between multipotent stromal cells (MSCs) and carcinoma and the possible use of MSCs in cell-based anti-cancer therapies. MSCs are present in multiple tissues and are defined as cells displaying the ability to differentiate in multiple lineages including chondrocytes, osteoblasts and adipocytes. Recent evidence suggests also that they could play a role in the progression of carcinogenesis and that MSCs could migrate towards primary tumors and metastatic sites. It is possible that MSCs could be also involved in the early stages of carcinogenesis through spontaneous transformation. In addition, it is thought that MSCs can modulate tumor growth and metastasis, although this issue remains controversial and not well understood. The immuno-suppressive properties and pro-angiogenic properties of MSCs account, at least in part, for their effects on cancer development. On the other hand, cancer cells also have the ability to enhance MSC migration. This complex dialog between MSCs and cancer cells is certainly critical for the outcome of tumor development. Interestingly, several studies have shown that MSCs engineered to express anti-tumor factors could be an innovative choice as a cell-mediated gene therapy to counteract tumor growth. More evidence will be needed to understand how MSCs positively or negatively modulate carcinogenesis and to evaluate the safety of MSCs use in cell-mediated gene strategies.
protein-1 (MIP-1 /CCL3), transforming growth factor (TGF-), and cytokines that induce the synthesis of other cytokines by the macrophages α β (in particular, the pro-inflammatory cytokines, IL-1 and tumor necrosis factor (TNF-)) . These cytokines can act at various levels of α 18 hematopoiesis, being at the same time negative regulators or growth factors (TGF-, MIP-1 ) according to the targeted cells and acting not β α only on the hematopoietic cells, but also on the stromal cells to control their proliferation (M-CSF, IL-6, TGF-, IL-1, TNF-) . MSCs express adhesion molecules which are mediators involved in the migration and homing of the cells to the bone marrow. They include the integrin family ( 1 1, 5 1), the immunoglobulin superfamily (inter-cellular adhesion molecule-1 (ICAM-1), vascular cell α β α β adhesion molecule-1 (VCAM-1), HCA), CD44, the ligand of hyaluronic acid, and other molecules of the extracellular matrix (ECM) , . In 19 20 addition, the stromal cells synthesize and assemble many molecules of the ECM: fibronectins, laminins, collagens, tenascins and syndecans and other glycosaminoglycans. Thus, molecules of the ECM are part of the architecture of the adherent layer allowing the anchoring of HSC and the site of accumulation of a great number of cytokines (Stem Cell Factor (SCF), IL-3, GM-CSF, M-CSF, TGF-, basic fibroblast growth β factor (bFGF), MIP-1 ) secreted by stromal cells . T lymphocytes (CTL)-mediated lysis and are able to inhibit CTL cytotoxicity in a dose-dependent manner when present at CTL priming , . 26 27 Although MSCs were reported to be unable to activate natural killers (NK) cells , they inhibit interferon-(IFN-) production by IL- 2 27 γ γ stimulated NK cells and are lysed by IL-2-activated NK cells , . 28 29 30 This suppressive effect of MSCs is dose-dependent, decreasing with lower amounts of MSCs in the mixed lymphocyte reaction (MLR), but a weak concentration of MSCs has been shown to have a stimulating effect on T cell proliferation , . The suppression of the immune 31 32 response is mediated by soluble factors after MSCs activation by culture in presence of immune cells, but their identity is still the object of controversy.
MSCs are a source of soluble factors involved in angiogenesis
Multipotent stromal cells express several pro-angiogenic factors including angiopoietin-1 (Ang-1), vascular endothelial growth factor (VEGF), growth factors such as Platelet-derived growth factor (PDGF), fibroblast growth factor (FGF)-2 and FGF-7, but also cytokines (IL-6, TNF-), as well as plasminogen activator , . All these molecules act synergistically on endothelial cells to promote vasculogenesis and α 33 34 angiogenesis. Moreover, MSCs express chemokines such as IL-8, which is involved in the recruitment of endothelial progenitors . 33
Multipotent stromal cells have been shown to activate endothelial cells, through soluble factors as well as cell contacts between the two types of cells. Indeed, MSCs induce vascular endothelial growth factor receptor 2 (Flk-1) and Tie2 expression on the target cells, and cell coculture resulted in a high expression of VEGF and Ang1, the corresponding ligand . Beside the promotion of angiogenesis, MSCs induce the 35 expression of junction proteins such as occludin and an increase in microvascular integrity . 35
Roles of multipotent stromal cells in carcinogenesis

Homing of Multipotent stromal cells to tumors (primary and metastases)
Several studies have demonstrated that MSCs have the ability into home to the primary tumor site and, eventually, to metastasis locations.
It is worthwhile to mention at this stage that the route of administration, the nature of the tumor cells, the location of the primary tumor and the type of MSCs injected appear to be the main determinants in the homing of MSCs.
The homing of MSCs in whole animals has first been investigated in the non-tumoral context. It was shown that allogeneic and autologous MSCs distributed to a wide range of tissues in baboons, including the lung, the thymus, the bone, the skin, the cerebellum and gastrointestinal tract . In rats, injection of MSCs led to an engraftment in the lung and thereafter in the liver . In mouse, MSCs home to many organs 36 37 including the lung, marrow, bone, skin, brain and spleen . In breast cancer patients, after i.v. infusion, human MSCs were detected in the 38 circulation of some patients, only within the first hour of injection . Patients with severe osteogenesis imperfecta, injected with MSCs, 39
displayed MSC engraftment in the marrow, the bone and the skin , whereas MSC DNA was detected in the colon and lymph node of a 40 patient treated with MSCs for steroid-resistant graft-versus-host-disease (GVHD) . In summary, based on these different studies, MSCs have 41 inserm-00271551, version 1 -3 Oct 2008 the ability to home to a wide range of organs, without specificity. In case of local inflammation, like in EAE (experimental autoimmune encephalomyelitis), Ucelli and coworkers showed that MSCs injected i.p. migrated to the subarachno dal space in close contact with the ï immune cells . This suggests that chronic inflammation might alter the homing of MSCs. 42
In the context of cancer, Houghton et al were the first to report, in a model of gastric cancer induced by helicobacter, that the transplantation of MSCs led to their engraftment into gastric glands . 43
A number of groups have been interested in the homing of MSCs towards glioblastoma. Using bone marrow multipotent stromal cells (BM-MSCs), it was shown that injection of MSCs in the contralateral hemisphere, into the carotid vein or the tail vein led to the homing of MSCs to the hemisphere bearing the tumor, suggesting that MSCs could cross the blood-brain barrier , . 44 45 MSCs are also able to target tumors which have been implanted subcutaneously (s.c.). Indeed, in a model of Kaposi s sarcoma (KS), human A recurrent question was the ability of MSCs to migrate to the metastatic sites and, in particular, to the lung. BM-MSCs injected into the tail vein of nude mice migrate to the lung metastases sites of mice bearing melanoma metastases , . However, one might argue that in this 49 50 type of setting, the ability of MSCs to migrate to metastatic sites is questionable as many types of cells home to the lung when injected iv.
Collectively, these studies suggest that MSCs can migrate towards the primary tumor and metastatic sites, although the homing is not completely specific of tumor cell locations. Indeed, in most cases, MSCs were also able to colonize organs which did not bear tumor cells, such as lung, kidney, liver or spleen. So, one might question the fact that MSC tropism is clearly dictated by the presence of tumor cells. The efficiency of MSCs homing to tumors is also questionable as there is no quantification of the percentage of MSCs, which really migrate to the carcinoma. One important point will be also to assess possible side effects of MSCs on other organs, as the homing of MSCs does not appear completely selective. Indeed, the engraftment sites of MSCs do not seem very different in the absence and the presence of carcinoma.
Furthermore, it is also important to mention that the issue of the homing of MSCs has been raised by using MSCs, which were injected in the animals. So far, there is no demonstration that, in the pathologic situation, MSCs detected in the primary tumor site, originate from the local mesenchyme or from bone-marrow. This will be a key question for future developments of anti-cancer therapies based on MSCs.
Potential effects of MSCs on tumor growth and development
In addition to the homing ability of MSCs, the main controversial issue remains their ability to modulate tumor growth. The results arise both from in vitro studies and in vivo studies, either by co-injection in the same sites of tumor cells with MSCs or, by the injection of MSCs at distance from the tumor. These are summarized in . figure 1 
Inhibition of tumor growth
The inhibition of tumor growth by MSCs has been observed in different types of animal models. Maestroni and colleagues first reported in experimental models of Lewis lung carcinoma and B16 melanoma that the co-injection of mouse MSCs with tumor cells inhibited primary tumor growth. Although the factors mediating the anti-tumor activity of MSCs were not identified by the authors, data from this study suggested that they were distinct from inflammatory cytokines . The anti-proliferative action of MSCs was also reported in a model of colon 51 carcinogenesis in rats, in which the co-injection of MSCs with tumor cells in a gelatin matrix implanted s.c. led to growth inhibition . In 52 addition, the coinjection of both cells triggered a more pronounced infiltration of monocytes and granulocytes . 52
Rat MSCs have the ability to migrate towards glioma cells and to inhibit their proliferation and, when implanted into the contralateral hemisphere, to migrate to the hemisphere bearing the tumor . When injected directly into the tumor, hSDSCs also reduce brain tumor size . 44 
Enhancement of tumor growth and development
Several studies show that MSCs can increase tumor growth. Fetal or adult MSCs injected s.c. together with tumor cells can favor tumor growth . This is accompanied by extensive necrosis and angiogenesis compared to mice injected only with tumor cells . Similar results 54 54 have been obtained with Raji cells which were injected s.c. . MSCs can also favor the growth of tumor cells within the bone. Indeed, 55 multiple myeloma malignancy (MM) leads to the formation of osteolytic lesions in the bone, which is enhanced by the interaction of MM with
MSCs . 56
Immunosuppression could be also one explanation for the enhancement of tumor growth by MSCs. We have shown that, when injected s.c.
into an allogenic recipient, melanoma cells led to tumor formation only in the presence of MSCs . Interestingly, the action of MSCs could 22 take place when MSCs were coinjected at the same site as tumor cells or when MSCs were injected at distance . 57
Only a few studies have begun to identify the molecules involved in the enhancement of cancer cell proliferation by MSCs. Indeed, breast cancer cells transfected with IL-6 showed enhanced growth . 59
No apparent effect
Some studies reported no effect on tumor growth. This was the case in a model of ovarian cancer, in which intra-peritoneally established xenografts were subsequently injected with bone marrow MSCs , and also of human adipose tissue-derived MSCs (AT-MSCs), which did 48 not modify colon cancer cell growth in vitro . Human MSCs seem also to have no effect in most cases on tumor growth of breast cancer cells 47 favor the in vivo tumor growth when coinjected s.c. to NOD/SCID mice . One other critical parameter seems also to be the ratio of MSCs 61 over cancer cells. We observed that murine MSCs co-injected with Renca tumor cells in syngeneic immunocompetent mice displayed different effects on the kinetics of subcutaneous tumor growth, depending on the proportion of each cell type. Indeed, the growth of the tumor was not affected by the co-injection of the same amounts of MSCs, but was increased in the presence of ten-fold more MSCs, although ten-fold less MSCs completely abolished tumor formation . 57
MSCs and Metastasis
So far, very few studies have addressed the question of the effects of MSCs on metastasis. It was shown that murine MSC could reduce metastasis in a model of Lewis lung carcinoma and B16 melanoma . A more recent study with human MSCs showed that, in most cases, 51
MSCs did not modify the growth of human breast cancer xenograft . However, the most striking result of this study was the fact that MSCs 60 could increase the metastasis rate of breast cancer cells through secretion of Rantes (CCL5) by MSCs, suggesting that the main adverse role of MSCs was its pro-invasive potential . It is likely that other molecules participate to the enhancement of metastasis by MSCs and this will be 60 the challenge of future studies.
In summary, depending on the nature of cancer cells and MSCs, on the integrity of the immune system of the mice that were injected, on the sites of injections; inhibition, enhancement or no apparent effect on tumor growth have been reported. One example of this complexity is shown in the study by the group of Weinberg, which showed that human MSCs did not affect tumor growth of MDA-MB-231 and MDA-MB-435 cells but increased the one of MCF-7/Ras cells , suggesting that the nature of cancer cells is critical. For these reasons, if one 60 wants to use MSCs in anti-cancer therapies, it will be essential to identify the factors produced by MSCs cells responsible for the inhibition or the enhancement of tumor growth and those governing the response of tumor cells. It is also interesting to note that cancer cells can modify the growth or migration of MSCs, making the picture even more complex. Indeed, when co-injected s.c. to nude mice with melanoma cancer cells, MSCs display an increased proliferation . In addition, it was shown recently that MCP-1 (CCL2) secreted by breast cancer cells increased the 49 migration of MSCs .
MSCs and their impact on tumoral angiogenesis
Angiogenesis of the developing neoplasia is a key event required for the optimal growth of the tumor and metastasis. MSCs could modulate this phenomenon, as suggested by some reports. By attracting endothelial cells and stimulating their proliferation, MSCs could contribute to metastasis development. This effect is related to expression of proangiogenic factors induced by interaction between carcinoma cells and MSCs. Indeed, when human MSCs are injected i.v. to SCID mice engrafted with melanoma cells, they colonize tumor vessels, which suggests that they could participate to angiogenesis . Indirect evidence suggests that MSCs increase tumor growth through an enhancement 63 of angiogenesis, as MSCs expressing truncated soluble vascular endothelial growth factor decoy receptor (tsFlk-1) had no effect on tumor growth, whereas unmanipulated MSCs increased both tumor growth and angiogenesis . The direct injection of hSDSCs in brain tumors has 55 also been shown to reduce angiogenesis . 53
MSCs and malignant transformation
As MSCs have the ability to expand, one might wonder whether these cells may also be the seed for new tumors. A number of approaches have been used to begin to answer this question. In particular, several groups analyzed whether MSCs could undergo spontaneous transformation or have attempted to engineer MSCs to determine whether they could be transformed. On the other hand, tumor MSCs have been isolated, which show differentiation abilities that are often close to those of original MSCs.
Are MSCs able to transform in vitro?
The issue of spontaneous transformation of MSCs is a matter of debate and if exists, seems to be an exceptional event. Rubio et al have shown that human AT-MSCs isolated from adipose tissue undergo spontaneous transformation after long term culture (4 5 months) . This 
Factors inducing transformation of MSCs in vitro
The immortalization and/or transformation of MSCs can also be triggered by the introduction of oncogenes. Indeed, human MSCs can be immortalized using HPV16 E6/E7 genes without neoplastic transformation, although the conditions of culture used by the authors could explain this result . These cell lines retain the ability to differentiate into osteoblasts, chondroblasts, adipocytes and neurons . On the other 71 71 hand, the transduction of MSCs with telomerase reverse transcriptase is sufficient to induce their transformation, leading to a population of cells with loss of contact inhibition, anchorage independence, and tumor formation in vivo , . Human MSCs do not express telomerase 72 73 reverse transcriptase (hTERT). hTERT expression is indeed repressed in MSCs through hypoacetylation of hTERT promoter . Furthermore, 74
human MSCs immortalized with hTERT and Bmi1 (a repressor of p16 ) and then transformed with H-RAS display anchorage-independent INK4A growth and increased invasion ability . They retain adipogenic and chondrogenic differentiation ability, but not the osteogenic potential. 75
MSCs are targets of oncogenic processes
In patients, other oncogenes have also the potential to transform MSCs. This is the case for EWS-FLI1, which is involved in the etiology of phenotype with the ability to differentiate into adipogenic and osteogenic lineage, suggesting that Ewing tumors could originate from MSCs
progenitors . 78
Are MSCs found in tumors identical to bone-marrow MSCs?
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Several teams have compared the properties of non-pathological MSCs with those of tumor MSCs. MSCs from MM patients exhibited a normal phenotype, adipogenic and osteogenic differentiation capacity, but a reduced efficiency to inhibit T-cell proliferation . The 79 comparison of bone marrow MSCs between healthy patients and MM patients showed a limited number of modifications, as only 145 genes, that are mainly involved in the tumor microenvironment (such as IL-1 , IL-6, SDF-1/CXCL12) were differentially expressed , . Giant cell β 79 80 tumors of bone (GCT) cells can also differentiate into osteoblasts as well as chondroblasts and adipocytes, suggesting that GCT stromal cells could originate from MSCs . In summary, MSCs have the ability to transform spontaneously or to be transformed with natural oncogenes. 81
This could represent a major limitation of their therapeutic use. Moreover, the comparison of MSCs found in healthy patients or patients harboring a cancer seem to have different transcriptomes. It will be essential to determine, whether MSCs found in tumors originate from the site of the tumor itself or, whether they come from the bone marrow.
Cross-talk between MSCs and bone cells
It appears very likely that MSCs could also affect metastasis development, in particular bone metastasis, due to their presence in great amounts in this location. Whether MSCs favors metastasis development or, on the contrary, could counteract osteolysis, remains controversial.
Based on several studies, it seems that cancer cells divert MSCs from their original functions to force them to participate in osteolysis. Sohara therapy to regenerate the bone. Indeed, MSC inoculation is associated with enhanced bone mineral density and the differentiation of MSCs in osteoblasts, even though these MSCs have mixed effects as tumor growth decreased in some animals but not in others . 83
Innovative cancer therapy through engineering of MSCs
Multipotent stromal cells (MSCs) possess numerous properties that might make them an attractive choice as a cell-mediated gene therapy in human malignancies , . MSCs have been shown to express transgenes efficiently and for an extended period without any defect in their 46 50 stem cell properties . If their ability to home to tumor sites is further demonstrated, MSCs might represent an attractive tool to deliver 84
anti-cancer drugs to the carcinoma. In order to achieve this, MSCs have been engineered in a number of different ways, either to deliver cytotoxic drugs, to stimulate the immune response or to block angiogenesis.
The first engineered MSCs were modified to express IFN-and were able to inhibit the growth of melanoma cells in vitro and in vivo , MSCs-IL-12 was primarily mediated by activation of NK cells and CD8 T cells in the inhibition of metastasis formation and primary tumor + growth.
In a recent report, adenovirally engineered primary mouse MSCs used to express the immunostimulatory chemokine CX3CL1 were i.v.
injected into syngeneic immunocompetent recipient bearing lung metastases of C26 colon carcinoma or B16 melanoma cells. These engineered MSCs were able to target tumoral but not normal tissue, inducing both innate and adaptive anticancer immunity response and thus prolonging the animals survival . Mouse MSCs adenovirally-transduced to express human NK4, an antagonist of hepatocyte growth factor, exert also (AT-MSCs), which were engineered to express cytosine deaminase (CD-AT-MSCs) . Interestingly, AT-MSCs and to a lesser degree, CD-AT-MSCs were less sensitive to 5-FU than cancer cells. In addition, CD-AT-MSCs inhibit the growth of colon carcinoma cells in vitro and in vivo in the presence of 5-FC, whereas AT-MSCs had no effect on cancer cells in the absence and the presence of 5-FC.
Conclusion
In summary, the evaluation of the potential use of MSCs in cell-based anti-cancer therapies is just starting. These cells have shown some promise as several studies have reported that a portion (which remains to be defined) of MSCs is able to migrate to the tumor site. However, this homing of MSCs is not selective and it will be important to evaluate possible side effects in organs which are not affected by the disease.
In addition, it remains unclear, whether endogenous MSCs found in the tumor site come from the bone marrow or originate from the local mesenchyme. Depending on the types of MSCs or tumor cells, the beneficial anti-tumoral effect of MSCs is highly variable. To elucidate this issue, the precise action of MSCs will need to be studied. The safety of using MSCs could be also questioned as MSCs can also undergo transformation. However, encouraging data come from studies using engineered MSCs, which have proven their efficiency as cell carriers for the delivery of various clinically relevant anticancer factors. Overall, MSCs represent great hope for cancer therapies, but a thorough in vivo evaluation of their potential risk will be pre-required step.
Fig. 1 A complex network of communication between MSCs and bone resident cells
In the bone, cancer cells reduce the ability of MSCs to differentiate into osteoblasts by secreting Dkk1. Cancer cells secrete also a number of factors involved in bone metastasis including CCL2, CTGF, PTHrP, IL-1, IL-6, IL-11 . MSCs secrete chemokines such as CCL5 and CXCL12 91 which increase cancer cell invasion. MSCs produce also IL-6, TGF-, MMP-14 and increase angiogenesis by acting on endothelial cells through β VEGF, Ang1 and tweak secretion.
